International Journal of Advanced and Integrated Medical Sciences

Register      Login

VOLUME 2 , ISSUE 3 ( July-September, 2017 ) > List of Articles


Role of Salivary Biomarkers for Early Detection of Oral Squamous Cell Carcinoma

Citation Information : Role of Salivary Biomarkers for Early Detection of Oral Squamous Cell Carcinoma. Int J Adv Integ Med Sci 2017; 2 (3):155-160.

DOI: 10.5005/jp-journals-10050-10096

License: CC BY 3.0

Published Online: 01-12-2017

Copyright Statement:  Copyright © 2017; The Author(s).



Oral cancer is a potentially fatal disease, which constitutes an important portion of tumors of the head and neck region. Among head and neck cancers, oral squamous cell carcinomas (OSCCs) constitute 90% of total cancers. Regardless of the fact that the oral cavity is easily accessible to the accumulation of carcinogens, most oral cancers are typically detected at an advanced stage leading to lower survival rate among subjects. Abnormal cellular products elucidated from malignant cells can be detected and measured in various body fluids including saliva, which constitute tumor markers. Saliva, an aqueous biological fluid, is in direct contact with the oral cancer lesion. Hence, the saliva in any stage of oral cancer constitutes abnormal deoxyribonucleic acid (DNA), acid (RNA), and protein molecules. Saliva, being a noninvasive diagnostic aid, can be an alternative to serum for early detection, status of chemotherapy regime, and also patient prognosis. This article aims at providing a brief overview of various salivary biomarkers and their implications in oral cancer.

How to cite this article

Gupta P. Role of Salivary Biomarkers for Early Detection of Oral Squamous Cell Carcinoma. Int J Adv Integ Med Sci 2017;2(3):155-160.

  1. Squamous cell carcinoma of the tongue in young adults: Increasing incidence and factors that predict treatment outcomes. Otolaryngol Head Neck Surg 2000 Jan;122(1):44-51.
  2. Multivariate predictors of occult neck metastasis in early oral tongue cancer. Otolaryngol Head Neck Surg 2004 Oct;131(4):472-476.
  3. Global cancer statistics, 2002. CA Cancer J Clin 2005 Mar-Apr;55(2):74-108.
  4. Exploring the reasons for delay in treatment of oral cancer. Am Dent Assoc 2008 Oct;139(10):1346-1352.
  5. Prognosis of oral pre-malignant lesions: significance of clinical, histopathological, and molecular biological characteristics. Crit Rev Oral Biol Med 2003 Jan;14(1):47-62.
  6. Chemokines and cytokines as salivary biomarkers for the early diagnosis of oral cancer. Int J Dent 2013 Oct;2013:813756.
  7. Biomarkers and molecular epidemiology and chemoprevention of oral carcinogenesis. Crit Rev Oral Biol Med 2000;11(1):92-122.
  8. Tumor markers: an overview. JIAOMR 2010 Jul-Sep; 22(3):147-150.
  9. Early diagnostic and treatment monitoring role of Cyfra 21-1 and TPS in oral squamous cell carcinoma. Cancer 1999;35:1018-1025.
  10. Circulating prolactin and TPS in monitoring the clinical course of male patients with metastatic tongue cancer: a preliminary study. Anticancer Res 1993 Jan-Feb;13(1):237-240.
  11. An insight into salivary markers in oral cancer. Dent Res J (Isfahan) 2013 May;10(3):287-295.
  12. Cancer biomarkers: are we ready for the prime time? Cancers (Basel) 2010 Mar;2(1):190-208.
  13. Clinical chemistry: Theory, analysis and correlation. St Louis: CV Mosby. 1984; 882-896
  14. ; Herberman, RB. Characteristics of the ideal tumor marker in holland-frei cancer medicine. 6th ed. Hamilton (ON): BC Decker; 2003.
  15. Oral carcinogenesis and oral cancer chemoprevention: a review. Pathol Res Int 2011 Mar;2013:431246.
  16. DNA cytometry of oral leukoplakia and oral lichen planus. Med Oral Patol Oral Cir Bucal 2005 Apr;10(Suppl 1):E9-E14.
  17. Tumor DNA content as a prognostic indicator in squamous cell carcinoma of the oral cavity and tongue base. Head Neck 1998 May;20(3):232-239.
  18. Loss of heterozygosity: a potential tool in management of oral premalignant lesions? J Oral Pathol Med 2001 Oct;30(9):513-520.
  19. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 1996 Jun;56(11):2488-2492.
  20. Predicting cancer development in oral leukoplakia: ten years of translational research. Clin Cancer Res 2000 May;6(5):1702-1710.
  21. Salivary markers for oral cancer detection. Open Dent J 2010 Aug;4:172-178.
  22. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993 Oct;53(19):4477-4480.
  23. Salivary biomarker development using genomic, proteomic and metabolomic approaches. Genome Med 2012 Oct;4(10):82.
  24. Salivary analysis of oral cancer biomarkers. Br J Cancer 2009 Oct;101(7):1194-1198.
  25. Association of Epstein-Barr virus with oral cancers. Hum Pathol 2002 Jun;33(6):608-614.
  26. Acid and alkaline ribonucleases of human parotid, submaxillary, and whole saliva. Arch Biochem Biophys 1964 Aug;107:197-208.
  27. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc 2006 Mar;137(3):313-321.
  28. John M.A.R, and. Wong D.T.W, “RNA profiling of cell-free saliva using microarray technology,” J Dent res 2004;83(3):199-203.
  29. Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res. 2009; 15:5473-5477.
  30. Genetic defects as tumor markers. Mol Biol 2003 Mar;37(2):159-169.
  31. A study of a new tumour marker, CYFRA 21-1, in squamous cell carcinoma of the head and neck, and comparison with squamous cell carcinoma antigen. Clin Otolaryngol 1998 Feb;23(1):82-86.
  32. Salivary levels of tumor necrosis factor-alpha in oral lichen planus. Mediators Inflamm 2004 Apr;13(2):131-133.
  33. Estimation of serological and salivary biomarkers in patients with oral squamous cell carcinoma, premalignant lesions and conditions. SRM Univ J Dent Sci 2010;1(1):14-19.
  34. A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 2008 Apr;34(4):450-455.
  35. Defensin-1, a peptide detected in the saliva of oral squamous cell carcinoma patients. Anticancer Res 1998 Nov-Dec;18(6B):4645-4649.
  36. Concomitant analysis of salivary tumor markers: a new diagnostic tool for oral cancer. Clin Cancer Res 2006 Jul;12(13):3979-3984.
  37. Intraoperative and postoperative kinetics of serum tumor markers in patients with oral carcinoma. J Oral Maxillofac Surg 1998 Dec;56(12):1390-1393.
  38. ; Sell, S. Tumor markers. In: Burtis CA, Ashwood ER, editors. Tietz's textbook of clinical chemistry. 2nd ed. Philadelphia (PA): WB Saunders; 1994. p. 897-925.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.